Chondroid metaplasia: a rare subtype of metaplastic breast carcinoma

Year 2020, Volume: 6 Issue: 1, 73 - 76, 04.01.2020

Semra Demirli Atıcı , Semra Salimoğlu Yasemin Kırmızı , Dilek Kuzukıran Cengiz Aydın

https://doi.org/10.18621/eurj.460263

Abstract

Metaplastic breast carcinoma (MBC)
is a subtype of breast malignant lesions which is very rare seen. Clinically,
MBC is more aggressive and has worse prognosis than other subtypes of breast
cancers. A 61-year-old female patient who had a rapidly enlarging and palpabl  mass on the left breast applied. Core biopsy
was performed and pathology was reported as  invasive ductal carcinoma. The patient who had
been diagnosed with breast cancer was  operated
and postoperative course was unremarkable. She was discharged postoperative
third day with no complication. Postoperative specimen pathology was reported as a rare
type of  breast metaplastic carcinoma
which was chondroid metaplasia. Here we aimed to report, a case of chondroid
metaplasia which is a rare type of metaplastic breast carcinoma with the
literature. 

Keywords

Metaplastic carcinoma, chondroid metaplasia, breast cancer

References

• 1. Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg 2006;191:657-64.
• 2. Nelson AR, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol 2015;22:24-31.
• 3. Salimoğlu S, Sert İ, Emiroğlu M, Karaali C, Kuzukıran D, Akyüz Kırmızı Y, et al. Metaplastic breast carcinoma: analysis of clinical and pathologic characteristics. J Breast Health 2016;12: 63-6.
• 4. Lakhani SR, Ellise IO, Schnitt SJ, Tan PH, van de Vijver MJ. editors. WHO classification of tumors of the breast. 4th ed. Lyon, France: IARC; 2012: p85-7.
• 5. Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007;101:349-53.
• 6. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the national cancer data base. Ann Surg Oncol 2007;14:166-73.
• 7. Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognosis factors. Acta Oncol 2006;45:188-95.
• 8. Cimino-Mathews A, Verma S, Figueroa-Magalhaes MC, Jeter SC, Zhang Z, Argani P, et al. A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. Am J Clin Pathol 2016;145:365-72.
• 9. Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat 2019;176:709-16.
• 10. Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol 2011;18:94-103.
• 11. PaulWright G, Davis AT, Koehler TJ, Melnik MK, Chung MH. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population‐based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol. 2014;21:3497‐503.
• 12. Taşdemir A, Oğuz A, Ünal D, Tuna Ö. Metaplastic carcinoma of the breast: a rare carcinoma with chondroid metaplasia. Ulusal Cer Derg 2014;30:57-9.